Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

Background: In the randomized, phase III, global SELECTCOMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, which was maintained over 48 weeks. This post hoc anal...

Full description

Saved in:
Bibliographic Details
Main Authors: Karel Pavelka (Author), Zoltán Szekanecz (Author), Nemanja Damjanov (Author), Branimir Anić (Author), Matija Tomšič (Author), Vadim Mazurov (Author), Marija Maksimovic (Author), Orsolya Nagy (Author), Jerzy Świerkot (Author), Tzvetanka Petranova (Author), Tiina Veldi (Author), Asta Baranauskaitė (Author), Catalin Codreanu (Author), Daina Andersone (Author), Roy Fleischmann (Author)
Format: Book
Published: BioExcel Publishing Ltd, 2020-10-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items